Genemarkers, LLC and Genoskin, Inc. announce partnership to advance clinical studies of topical solutions
September 18, 2019 – Kalamazoo, MI & Salem, MA
Genemarkers and Genoskin are pleased to announce they have formed a partnership to provide exceptional value and service to researchers in the fields of cosmetic and pharmaceutical topical solutions. The Companies are currently performing collaborative work to understand how cannabidiol (CBD) acts in the skin.
Genemarkers is a leader in applying state-of-the-art genomics technologies to personal care, nutritional and pharmaceutical research. Working with a wide range of customers, Genemarkers’ gene expression profiling and genotyping services help identify biomarkers and elucidate biological mechanisms of action for new products. The data is used to enhance the product development process and validates the efficacy of topical products.
Genoskin is the global leader in providing the cosmetic, chemical, and pharmaceutical industry with ready-to-use immunocompetent and injectable human skin assays. Their ex vivo human skin models simplify the culture, treatment, and manipulation of human skin for research and analysis. Their technology accelerates product development while de-risking clinical testing.
“We have worked with Genoskin models in many of our studies,” says Anna Langerveld, President and Chief Scientific Officer of Genemarkers. “Their real human skin models provide a much-needed bridge between in vitro work and clinical studies. Validating efficacy in Genoskin’s ex vivo models helps streamline costs and ensure a successful clinical trial.” Pascal Descargues, Founder and Chief Executive Officer of Genoskin adds, “as we look at the future of product development and consider how to enhance our products and services to better serve our clients, a formal partnership with Genemarkers only makes sense. Working together will allow us to streamline procurement, reduce the total time from proposal to report, and save our clients money while delivering industry-leading clinical-grade results.”
To learn about how Genemarkers & Genoskin can advance your research, please contact Anna Langerveld at Genemarkers at or Pascal Descarguesat Genoskin at . For further information about Genemarkers, visit genemarkersllc.com. For further information about Genoskin, visit genoskin.com.
Comments are closed.
